MitraClip: Impact of Sinus Rhythm and Heart Rate

MitraClip: Impact of Sinus Rhythm and Heart RateCourtesy of Dr. Carlos Fava.

Atrial fibrillation (AF) and fast heart rate (>70 lpm) have been shown to increase the risk of mitral valve repair surgery. The MitraClip has shown benefits in high risk patients, but its relation to abnormal heart rhythm has not yet been established.

 

760 patients were analyzed; 315 (52.4%) presented sinus rhythm (SR) and 286 (47.6%) atrial fibrillation. In the SR group, 365 patients (46.8%) presented a ≤70 lpm heart rate, and 404 (53.2%), a >70 lpm heart rate.

 

AF patients were older, had mild ventricular deterioration, and larger left auricular diameter. On the other hand, SR patients more often presented a history of MI, diabetes, (especially those with <70 heart rate), severe left ventricular function deterioration and increased end-diastolic volume.

 

Procedural success was 97.5%, with no significant differences between subgroups as regards:

  • procedural time
  • fluoroscopy
  • number of clips implanted
  • intra-procedural complications

 

There were no differences as regards in hospital stay, though SR patients presenting <70 lpm heart rate saw a shorter stay.

 

At 30 days, there were no differences in mortality (SR 3%, AF 5.8%, SR≤70 4.3% and SR>70 4.5%). The only mortality predictor was a >2 mg/dl creatinine value. Functional class saw sustained improvement across all subgroups.

 

Conclusion

These registry data (comparing a large “real world” unselected series of patients with mitral regurgitation receiving MitraClip) suggest that this intervention is safe and effective and that it reduces mitral regurgitation in most patients, regardless of baseline sinus rhythm or heart rate. While at 12 months survival rate was higher for those in SR, MACE and clinical improvement was no different between the groups.

 

Editorial Comment

This analysis of the German registry shows the MitraClip has benefits for high risk patients regardless of sinus rhythm or heart rate, as opposed to mitral valve surgery.

 

It is important to intervene before kidney failure, since this has a negative impact on results.

 

We need to evaluate these outcomes against those of larger studies.

 

Courtesy of Dr. Carlos Fava. Favaloro Foundation, Buenos Aires, Argentina.

 

Original Title: Effects of atrial fibrillation and heart rateo in percutaneous mitral valve repair with MitraClip: results from the TRAnscatheter Mitral valve Intervention (TRAMI) registry.

Reference: Alexnader Jabs et al. EuroIntervention 2017;12:1697-1705.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

T-TEER: Beyond Traditional Pulmonary Hypertension Thresholds

Significant tricuspid regurgitation (TR) is associated with progressive functional deterioration, heart failure (HF) hospitalizations, and increased mortality. In recent years, transcatheter tricuspid edge-to-edge repair...

Is left atrial appendage closure safe in patients with reduced ejection fraction?

Patients with heart failure with reduced ejection fraction (HFrEF) were excluded from the major randomized trials evaluating percutaneous left atrial appendage closure (LAAC), and...

Left Atrial Appendage Closure in Spain: Sustained Growth and Favorable Real-World Outcomes

Oral anticoagulation remains the standard treatment for stroke prevention in patients with atrial fibrillation. However, many patients have a high bleeding risk or contraindications...

HERA-TAVI: Intra-Annular vs Supra-Annular Valves in TAVI

 The HERA-TAVI study is an international multicenter registry that compared the clinical and hemodynamic outcomes of contemporary self-expanding transcatheter heart valves with intra-annular (IA)...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

Plaque Ruptures in Non-Culprit Arteries: Follow-Up With Intravascular Imaging

Plaque rupture remains one of the most important pathophysiological mechanisms in acute coronary syndromes. However, not all ruptures manifest clinically as ischemia, myocardial infarction,...

Drug-Eluting Stents in Peripheral Arterial Disease: When Should They Be Used?

Peripheral drug-eluting stents have transformed the treatment of peripheral arterial disease by reducing restenosis rates and the need for repeat interventions. However, the emergence...

OCT-Detected High-Risk Plaques Predict Recurrent Events After Myocardial Infarction

After a myocardial infarction (MI), non-culprit lesions are often deferred when they are not flow-limiting (negative FFR). However, these lesions continue to represent an...